Advanced Enzymes Q1 FY27: Profit down 7.5%, buyback

Results announced after August 8 board meeting

Advanced Enzyme Technologies announced its first-quarter results for FY2026-27 on Saturday, August 8, alongside multiple board approvals. The quarter under review ended June 30, 2026. The company reported softer profitability on year-on-year metrics, even as revenue showed a marginal increase in one of the reported sets of numbers.

Along with the financial results, the board approved a share buyback through the open market route and cleared steps to increase its holding in a subsidiary. The meeting also included an approval for additional funding into a wholly owned subsidiary.

Profit declines, while revenue shows a modest uptick

For the quarter, the company reported net profit of ₹37 crore, a 7.5% decline versus ₹40 crore in the comparable period mentioned. Revenue rose 2.2% to ₹190 crore from ₹186 crore.

Profitability weakened more visibly at the operating level. EBITDA declined to ₹51.1 crore from ₹56.5 crore, a 9.6% year-on-year fall. This was accompanied by a contraction in EBITDA margin to 26.9% from 30.38%.

The combination of higher costs and a softer margin profile meant the revenue increase did not translate into higher profit. The reported margin movement highlights that the quarter was largely defined by operating pressure rather than a volume-driven expansion.

Consolidated and standalone quarterly numbers disclosed

In the unaudited results approved by the board for the quarter ended June 30, 2026, the company reported consolidated revenue from operations of ₹189.79 crore and consolidated net profit of ₹38.59 crore.

On a standalone basis for the same quarter, net profit was reported at ₹22.35 crore, with revenue from operations at ₹115.86 crore. The company also disclosed that net profit attributable to shareholders stood at ₹37.09 crore for the quarter ended June 30, 2026, compared with ₹39.93 crore in the corresponding quarter of the previous year.

The statutory auditors reviewed the unaudited consolidated financial results and expressed an unmodified conclusion, as stated in the disclosures.

Key corporate actions: buyback, subsidiary stake purchase, fund infusion

The board approved a buyback of fully paid-up equity shares with a face value of ₹2 each, at a price not exceeding ₹500 per share. The aggregate buyback size will not exceed ₹69.70 crore. At the maximum price and size, the indicative maximum number of shares to be bought back is 13,94,000, representing 1.24% of the existing paid-up equity capital.

The buyback will be executed via the “Open Market” route through the stock exchange mechanism. It will be conducted from shareholders other than promoters, the promoter group, and persons in control of the company, and will be in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013.

Separately, the board approved the acquisition of the remaining 4.28% stake in JC Biotech Private Limited, taking the subsidiary from 95.72% holding to wholly owned status upon completion. The total consideration for this stake purchase was approved at ₹7.98 crore. The board also approved an additional fund infusion of up to ₹2 crore in Advanced Nutrazyme Private Limited.

Buyback sizing in context of reserves

As per the disclosure, the maximum buyback size represents 9.99% and 5.09% of the aggregate of the total paid-up equity share capital and free reserves, based on the latest audited standalone and consolidated financial statements as on March 31, 2026, respectively.

This framing is relevant because the buyback ceiling is linked to capital and reserve thresholds under applicable regulations. The company’s use of the open market route also defines how the execution may take place, subject to regulatory conditions and market availability.

Trading window closure and compliance details

Ahead of the results and board decisions, the company stated that the trading window remained closed until August 10, 2026, in line with SEBI regulations around insider trading prevention. The closure had been previously intimated and extended through the post-results period as per the stated timeline.

The board meeting agenda included approval of unaudited standalone and consolidated results for the quarter ended June 30, 2026, and consideration of the buyback proposal and related matters.

Dividend record date and payment timeline

Advanced Enzyme Technologies also disclosed a final dividend of ₹1.35 per equity share for FY2025-26. The record date to determine shareholder eligibility was July 24, 2026.

The dividend was approved by shareholders at the Annual General Meeting held on July 31, 2026, and was paid on August 5, 2026, as stated.

Stock movement and recent price trend

On the market side, shares of Advanced Enzyme Technologies closed lower by 1.79%, or ₹5.90, after the announcements referenced. Over the past six months, the stock price was reported to have risen 11.08%, taking it to ₹323.90 per share.

A separate market snapshot referenced a CMP of ₹315 and market capitalisation of ₹3,528 crore in the context of the board meeting update dated August 1, 2026.

Snapshot table: financials and board approvals

Consolidated quarterly comparison shared by the company

Why the developments matter for investors

The quarter’s disclosed numbers point to a period where margins and operating profit weakened even as headline revenue held up. For investors tracking earnings quality, the EBITDA decline and margin compression are central data points because they signal operating pressure within the quarter.

On capital allocation, the buyback approval sets a clear ceiling on price, quantity, and size, while the open market route clarifies the mechanism. The subsidiary stake purchase and additional fund infusion indicate ongoing corporate structuring steps, with JC Biotech moving to wholly owned status once the acquisition completes.

Conclusion

Advanced Enzyme Technologies’ Q1 FY27 disclosures combined softer profitability with a set of board-led capital and subsidiary actions. The next confirmed milestone from the company’s compliance timeline is the end of the trading window closure on August 10, 2026, following the August 8 board meeting decisions.